BDPOMA contains pomalidomide, an oral medication used in the treatment of certain blood cancers, especially multiple myeloma. It belongs to a class of drugs known as immunomodulatory agents, closely related to thalidomide and lenalidomide. Pomalidomide is typically used when other treatments have not been effective, making it a valuable option for patients with relapsed or refractory disease.

This medicine is usually given in combination with other agents such as dexamethasone to enhance its effectiveness. It is administered under strict medical supervision due to its powerful effects and the need for careful monitoring.

Mechanism of Action

Pomalidomide works through multiple pathways to attack cancer:

• It enhances the immune system by stimulating certain white blood cells, particularly T-cells and natural killer cells, to attack cancer cells

• It inhibits angiogenesis, which means it prevents the formation of new blood vessels that supply tumors

• It directly inhibits the growth of myeloma cells and induces their programmed cell death

  Uses

  BDPOMA (pomalidomide) is primarily used in the treatment of:

  • Multiple myeloma, especially in patients who have already been treated with at least two other therapies including lenalidomide and a proteasome inhibitor and whose disease has progressed

  • Investigational or off-label use in certain other cancers may occur in clinical settings

    Adverse Effects

    Pomalidomide is a potent medication and, like other cancer therapies, can lead to a range of side effects.

    Common Side Effects

    • Fatigue

    • Constipation or diarrhea

    • Nausea

    • Dizziness

    • Rash

    • Reduced appetite